Vinceti M, Balboni E, Rothman KJ, Teggi S, Bellino S, Pezzotti P, Ferrari F, Orsini N, Filippini T. Substantial impact of mobility restrictions on reducing COVID-19 incidence in Italy in 2020. J Travel Med. 2022 Sep;29(6):taac081. doi: 10.1093/jtm/taac081
Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm. 2014 Apr;22(2):96-101. doi: 10.3109/09273948.2013.812222
Arnold LM, Williams DA, Hudson JI, Martin SA, Clauw DJ, Crofford LJ, Wang F, Emir B, Lai C, Zablocki R, Mease PJ. Development of responder definitions for fibromyalgia clinical trials. Arthritis Rheum. 2012 Mar 1;64(3):885-94.
Martel JN, Esterberg E, Nagpal A, Acharya NR. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm. 2012 Feb;20(1):18-26. doi: 10.3109/09273948.2011.633205.
Mirabelli MC, Zock JP, Bircher AJ, Jarvis D, Keidel D, Kromhout H, Norbäck D, Olivieri M, Plana E. Metalworking exposures and persistent skin symptoms in the ECRHS II and SAPALDIA 2 cohorts. Contact Dermatitis. 2009 May;60(5):256-63.
Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Presented at the 2008 Annual Meeting of the American College of Rheumatology; October 2008. San Francisco, CA. [abstract] Arthritis Rheum. 2008 Sep; 58(9 Suppl):S782.
Keeenan AM, McKenna SP, Doward LC, Conaghan PC, Emery P, Tennant A. OAQoL: the development and validation of a needs-based quality of life instrument for osteoarthritis. Arthritis Rheum. 2008 Jun 1;59(6):841-8.